• Medientyp: E-Artikel
  • Titel: The role of re-resection in recurrent hepatocellular carcinoma
  • Beteiligte: Bednarsch, Jan; Czigany, Zoltan; Heij, Lara R.; Amygdalos, Iakovos; Heise, Daniel; Bruners, Philip; Ulmer, Tom F.; Neumann, Ulf P.; Lang, Sven A.
  • Erschienen: Springer Science and Business Media LLC, 2022
  • Erschienen in: Langenbeck's Archives of Surgery, 407 (2022) 6, Seite 2381-2391
  • Sprache: Englisch
  • DOI: 10.1007/s00423-022-02545-1
  • ISSN: 1435-2451
  • Schlagwörter: Surgery
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Abstract Purpose While liver resection is a well-established treatment for primary HCC, surgical treatment for recurrent HCC (rHCC) remains the topic of an ongoing debate. Thus, we investigated perioperative and long-term outcome in patients undergoing re-resection for rHCC in comparative analysis to patients with primary HCC treated by resection. Methods A monocentric cohort of 212 patients undergoing curative-intent liver resection for HCC between 2010 and 2020 in a large German hepatobiliary center were eligible for analysis. Patients with primary HCC (n = 189) were compared to individuals with rHCC (n = 23) regarding perioperative results by statistical group comparisons and oncological outcome using Kaplan–Meier analysis. Results Comparative analysis showed no statistical difference between the resection and re-resection group in terms of age (p = 0.204), gender (p = 0.180), ASA category (p = 0.346) as well as main preoperative tumor characteristics, liver function parameters, operative variables, and postoperative complications (p = 0.851). The perioperative morbidity (Clavien-Dindo ≥ 3a) and mortality were 21.7% (5/23) and 8.7% (2/23) in rHCC, while 25.4% (48/189) and 5.8% (11/189) in primary HCC, respectively (p = 0.851). The median overall survival (OS) and recurrence-free survival (RFS) in the resection group were 40 months and 26 months, while median OS and RFS were 41 months and 29 months in the re-resection group, respectively (p = 0.933; p = 0.607; log rank). Conclusion Re-resection is technically feasible and safe in patients with rHCC. Further, comparative analysis displayed similar oncological outcome in patients with primary and rHCC treated by liver resection. Re-resection should therefore be considered in European patients diagnosed with rHCC.